science
ARPA-H jumps on mRNA dogpile
President Biden's fledgling health agency is designed to accelerate under-funded research, but it's set its sights on an area where the drug industry is already making multibillion-dollar investments, Damian and Sarah write.
The White House announced Wednesday that the Advanced Research Projects Agency for Health would bankroll a $24 million project by Emory University to build messenger RNA platforms to target "cancer and other diseases," investing in the technology behind the U.S.'s most commonly used vaccines for Covid-19. But BioNTech and Moderna have already said that cancer is their next target.
Read more, including how ARPA-H Director Renee Wergzyn is hoping to leverage a unique relationship with the FDA.
drug shortages
Not FDA's problem
FDA Commissioner Rob Califf said Tuesday that the agency cannot fix the fundamental cause of drug shortages of chemotherapies and other drugs.
Califf's comments during an Alliance for a Stronger FDA event are interesting in light of the debate that's brewing between Republicans and Democrats over how to fix the drug shortage crisis. Democrats in the House want to give the FDA more authority. Republicans want to deal with what they say are the underlying economic causes, and they're wary of giving the FDA more power. The White House task force on drug shortages hasn't stepped in to referee.
The FDA can help plug holes when shortages occur, Califf said, and the agency is getting better at that. He also said the agency needs better information from drug makers to understand what's happening in the supply chain. But he said the fundamental cause of drug shortages are economic.
"It's not the FDA's job to fix that," Califf said.
No comments